Role of NF-κB in thyroid cancer

Molecular and Cellular Endocrinology

Volumn 321, Issue 1, 2010, Pages 29-35

  Pacifico, Francesco ^a   Leonardi, Antonio ^b  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Apoptosis; Inflammation; NF B; Thyroid cancer

Indexed keywords

B RAF KINASE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN PATCHED; PROTEIN RET; TRANSCRIPTION FACTOR RELA;

APOPTOSIS; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HUMAN; INFLAMMATION; MALIGNANT TRANSFORMATION; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TRANSCRIPTION INITIATION; BIOLOGICAL MODEL; METABOLISM; PATHOLOGY; THYROID TUMOR;

APOPTOSIS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; NF-KAPPA B; THYROID NEOPLASMS;

EID: 77950920909     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.10.010     Document Type: Review

References (75)

1. Arif S., Blanes A., Diaz-Cano S.J. Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology 2002, 41:357-362.
2. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 2009, 8(1):33-40.
3. Boise L.H., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., Mao X., Nuñez G., Thompson C.B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993, 74:597-608.
4. Borrello M.G., Alberti L., Fischer A., Degl'innocenti D., Ferrario C., Gariboldi M., Marchesi F., Allavena P., Greco A., Collini P., Pilotti S., Cassinelli G., Bressan P., Fugazzola L., Mantovani A., Pierotti M.A. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:14825-14830.
5. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 2009, 8:33-40.
6. Castellone M.D., Guarino V., De Falco V., Carlomagno F., Basolo F., Faviana P., Kruhoffer M., Orntoft T., Russell J.P., Rothstein J.L., Fusco A., Santoro M., Melillo R.M. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 2004, 23:5958-5967.
7. Chandler N.M., Canete J.J., Callery M.P. Increased expression of NF-kappa B subunits in human pancreatic cancer cells. J. Surg. Res. 2004, 118:9-14.
8. Claudio E., Brown K., Park S., Wang H., Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat. Immunol. 2002, 3:958-965.
9. Cogswell P.C., Guttridge D.C., Funkhouser W.K., Baldwin A.S. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 2000, 19:1123-1131.
10. De Falco V., Guarino V., Avilla E., Castellone M.D., Salerno P., Salvatore G., Faviana P., Basolo F., Santoro M., Melillo R.M. Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res. 2007, 67:11821-11829.
11. Dejardin E., Droin N.M., Delhase M., Haas E., Cao Y., Makris C., Li Z.W., Karin M., Ware C.F., Green D.R. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002, 17:525-535.
12. De Smaele E., Zazzeroni F., Papa S., Nguyen D.U., Jin R., Jones J., Cong R., Franzoso G. Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature 2001, 414:308-313.
13. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C. IAPs block apoptotic events induced by caspase 8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17:2215-2223.
14. Fagin J.A., Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22:955-969.
15. Festa M., Petrella A., Alfano S., Parente L. R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway. Int. J. Cancer 2009, 124:2728-2736.
16. Gallel P., Pallares J., Dolcet X., Llobet D., Eritja N., Santacana M., Yeramian A., Palomar Asenjo V., Lagarda H., Mauricio D., Encinas M., Matias-Guiu X. Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. Hum. Pathol. 2008, 39:994-1001.
17. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109:S81-S96.
18. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 1998, 16:225-260.
19. Gimm O. Thyroid cancer. Cancer Lett. 2001, 163:143-156.
20. Gombos K., Zele E., Kiss I., Varjas T., Puskás L., Kozma L., Juhász F., Kovács E., Szanyi I., Ember I. Characterization of microarray gene expression profiles of early stage thyroid tumours. Cancer Genom. Proteomics 2007, 4:403-409.
21. Greten F.R., Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004, 206:193-199.
22. Guigon C.J., Zhao L., Willingham M.C., Cheng S.Y. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 2009, 28:509-517.
23. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
24. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
25. Helbig G., Christopherson K.W., Bhat-Nakshatri P., Kumar S., Kishimoto H., Miller K.D., Broxmeyer H.E., Nakshatri H. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem. 2003, 278:21631-21638.
26. Iannetti A., Pacifico F., Acquaviva R., Lavorgna A., Crescenzi E., Vascotto C., Tell G., Salzano A., Scaloni A., Vuttariello E., Chiappetta G., Formisano S., Leonardi A. The Neutrophil Gelatinase-Associated Lipocalin (NGAL), a NF-κB regulated gene, is a survival factor for thyroid neoplastic cells. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14058-14063.
27. Karger S., Weidinger C., Krause K., Sheu S.Y., Aigner T., Gimm O., Schmid K.W., Dralle H., Fuhrer D. FOXO3a: a novel player in thyroid carcinogenesis?. Endocr Relat Cancer 2009, 16:189-199.
28. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF [kappa]B activity. Annu. Rev. Immunol. 2000, 18:621-663.
29. Karin M., Cao Y., Greten F.R., Li Z.W. NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2:301-310.
30. Kato Y., Ying H., Zhao L., Furuya F., Araki O., Willingham M.C., Cheng S.Y. PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 2006, 25:2736-2747.
31. Kayagaki N., Yan M., Seshasayee D., Wang H., Lee W., French D.M., Grewal I.S., Cochran A.G., Gordon N.C., Yin J., Starovasnik M.A., Dixit V.M. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002, 17:515-524.
32. Keates S., Hitti Y.S., Upton M., Kelly C.P. Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells. Gastroenterology 1997, 113:1099-1109.
33. Kucharczak J., Simmons M.J., Fan Y., Gelinas C. To be or not to be: NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene 2003, 22:8961-8982.
34. Larson S.D., Jackson L.N., Riall T.S., Uchida T., Thomas R.P., Qiu S., Evers B.M. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J. Am. Coll. Surg. 2007, 204:764-773.
35. Ludwig L., Kessler H., Wagner M., Hoang-Vu C., Dralle H., Adler G., Böhm B.O., Schmid R.M. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res. 2001, 61:4526-4535.
36. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
37. Mechler C., Bounacer A., Suarez H., Saint Frison M., Magois C., Aillet G., Gaulier A. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. Br. J. Cancer. 2001, 85:1831-1877.
38. Melillo R.M., Castellone M.D., Guarino V., De Falco V., Cirafici A.M., Salvatore G., Caiazzo F., Basolo F., Giannini R., Kruhoffer M., Orntoft T., Fusco A., Santoro M. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 2005, 115:1068-1081.
39. Memon A., Radovanovic Z., Suresh A. Epidemiological evidence for a link between postpartum thyroiditis and thyroid cancer. Eur. J. Epidemiol. 2004, 19:607-609.
40. Mitsiades C.S., McMillin D., Kotoula V., Poulaki V., McMullan C., Negri J., Fanourakis G., Tseleni-Balafouta S., Ain K.B., Mitsiades N. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J. Clin. Endocrinol. Metab. 2006, 91:4013-4021.
41. Mitsiades C.S., Hayden P., Kotoula V., McMillin D.W., McMullan C., Negri J., Delmore J.E., Poulaki V., Mitsiades N. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. J. Clin. Endocrinol. Metab. 2007, 92:4845-4852.
42. Nikiforova M.N., Caudill C.M., Biddinger P., Nikiforov Y.E. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int. J. Surg. Pathol. 2002, 10:15-22.
43. Okladnova O., Poleev A., Fantes J., Lee M., Plachov D., Horst J. The genomic organization of the murine Pax 8 gene and characterization of its basal promoter. Genomics. 1997, 42:452-461.
44. Pacifico F., Mauro C., Barone C., Crescenzi E., Mellone S., Monaco M., Chiappetta G., Terrazzano G., Liguoro D., Vito P., Consiglio E., Formisano S., Leonardi A. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J. Biol. Chem. 2004, 279:54610-54619.
45. Pacifico F., Leonardi A. NF-kappaB in solid tumors. Biochem. Pharmacol. 2006, 72:1142-1152.
46. Pacifico F., Paolillo M., Chiappetta G., Crescenzi E., Arena S., Scaloni A., Monaco M., Vascotto C., Tell G., Formisano S., Leonardi A. RbAp48 is a target of nuclear factor-kappaB activity in thyroid cancer. J. Clin. Endocrinol. Metab. 2007, 92:1458-1466.
47. Palona I., Namba H., Mitsutake N., Starenki D., Podtcheko A., Sedliarou I., Ohtsuru A., Saenko V., Nagayama Y., Umezawa K., Yamashita S. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 2006, 147:5699-5707.
48. Pham C.G., Bubici C., Zazzeroni F., Papa S., Jones J., Alvarez K., Jayawardena S., De Smaele E., Cong R., Beaumont C., Torti F.M., Torti S.V., Franzoso G. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004, 119:529-542.
49. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
50. Pufnock J.S., Rothstein J.L. Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J. Immunol. 2009, 182:5498-5506.
51. Rhoden K.J., Unger K., Salvatore G., Yilmaz Y., Vovk V., Chiappetta G., Qumsiyeh M.B., Rothstein J.L., Fusco A., Santoro M., Zitzelsberger H., Tallini G. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J. Clin. Endocrinol. Metab. 2006, 91:2414-2423.
52. Rothwarf D.M., Zandi E., Natoli G., Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998, 395:297-300.
53. Russell J.P., Shinohara S., Melillo R.M., Castellone M.D., Santoro M., Rothstein J.L. Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene 2003, 22:4569-4577.
54. Saltman B., Singh B., Hedvat C.V., Wreesmann V.B., Ghossein R. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery 2006, 140:899-905.
55. Sautin Y., Takamura N., Shklyaev S., Nagayama Y., Ohtsuru A., Namba H., Yamashita S. Ceramide-induced apoptosis of human thyroid cancer cells resistant to apoptosis by irradiation. Thyroid 2000, 10:733-740.
56. Senftleben U., Cao Y., Xiao G., Greten F.R., Krähn G., Bonizzi G., Chen Y., Hu Y., Fong A., Sun S.C., Karin M. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293:1495-1499.
57. Sheils O.M., O'eary J.J., Uhlmann V., Lättich K., Sweeney E.C. ret/PTC-1 activation in Hashimoto thyroiditis. Int. J. Surg. Pathol. 2000, 8:185-189.
58. Sheils O., Smyth P., Finn S., Sweeney E.C., O'Leary J.J. RET/PTC rearrangements in Hashimoto's thyroiditis. Int. J. Surg. Pathol. 2002, 10:167-168.
59. Sherman S.I. Thyroid carcinoma. The Lancet 2003, 361:501-511.
60. 2-terminal kinase by growth factors influences survival but not apoptosis of human thyrocytes. Thyroid 2001, 11:629-636.
61. Smallridge R.C., Marlow L.A., Copland J.A. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 2009, 16:17-44.
62. Starenki D., Namba H., Saenko V., Ohtsuru A., Yamashita S. Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J. Clin. Endocrinol. Metab. 2004, 89:410-418.
63. Starenki D.V., Namba H., Saenko V.A., Ohtsuru A., Maeda S., Umezawa K., Yamashita S. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin. Cancer Res. 2004, 10:6821-6829.
64. Tak P.P., Firestein G.S. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 2001, 107:7-11.
65. Tang G., Minemoto Y., Dibling B., Purcell N.H., Li Z., Karin M., Lin A. Inhibition of JNK activation through NF-kappaB target genes. Nature 2001, 414:313-317.
66. Tirrò E., Consoli M.L., Massimino M., Manzella L., Frasca F., Sciacca L., Vicari L., Stassi G., Messina L., Messina A., Vigneri P. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res. 2006, 66:4263-4272.
67. Vallabhapurapu S., Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 2009, 27:693-733.
68. Vasudevan K.M., Gurumurthy S., Rangnekar V.M. Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol. Cell. Biol. 2004, 24:1007-1021.
69. Visconti R., Cerutti J., Battista S., Fedele M., Trapasso F., Zeki K., Miano M.P., de Nigris F., Casalino L., Curcio F., Santoro M., Fusco A. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 1997, 15:1987-1994.
70. Yamaoka S., Courtois G., Bessia C., Whiteside S.T., Weil R., Agou F., Kirk H.E., Kay R.J., Israël A. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 1998, 93:1231-1240.
71. Yeh W.C., Itie A., Elia A.J., Ng M., Shu H.B., Wakeham A., Mirtsos C., Suzuki N., Bonnard M., Goeddel D.V., Mak T.W. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 2000, 12:633-642.
72. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
73. Wang C.Y., Guttridge D.C., Mayo M.W., Baldwin A.S. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 1999, 19:5923-5929.
74. Xiao G., Cvijic M.E., Fong A., Harhaj E.W., Uhlik M.T., Waterfield M., Sun S.C. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J. 2001, 20:6805-6815.
75. Zhu W., Ou Y., Li Y., Xiao R., Shu, Zhou Y., Xie J., He S., Qiu P., Yan G. A small molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol. Pharmacol. 2009, 75:812-819.